

REMARKS

The specification has been amended to include some structures that were omitted at page 7. Support for the amendments to the specification can be found in the application in claim 1 at page 417.

Claims 40 to 51 were pending. Claim 49 has been canceled, claims 40, 50, and 51 have been amended, and claims 52 to 64 have been added. Claims 40 to 48 and 50 to 64 will be pending and under examination after entry of this amendment.

Claim 40 has been amended to recite that G1, G2, and G3 are all -CH₂-.

The Examiner indicated on page three of the August 19, 2005 Office Action that this subject matter was allowable. Claims 41 to 48 depend from claim 40. Claims 50 and 51, which formerly depended from claim 40, have been rewritten as independent claims. Claims 50 and 51 recite a pharmaceutical composition and a method of preparing a pharmaceutical composition comprising a compound of claim 40.

The Examiner indicated that the subject matter of claims 41 and 49 was allowable. Claim 41 has been rewritten as independent claim 52. Claims 53 to 59 depend from claim 52 and correspond to claims 42 to 48. Claims 60 and 61 are independent claims that recite a pharmaceutical composition and a method of preparing a pharmaceutical composition comprising a compound of claim 52. Claim 49 has been canceled and replaced by claim 62. Claims 63 and 64 are independent claims that recite a pharmaceutical composition and a method of preparing a pharmaceutical composition comprising the compound of claim 62.

The Examiner rejected claims 40, 42 to 48, and 50 to 51 under 35 U.S.C. § 112, first paragraph, as failing to comply with the written description requirement.

Applicants respectfully traverse this rejection of the claims. Although Applicants disagree with the Examiner, the claims have been amended to recite

subject matter the Examiner considers to be allowable. Accordingly, Applicants respectfully request that the Examiner withdraw this rejection of the claims.

In view of the above amendments and remarks, Applicants respectfully request that the Examiner withdraw the rejections of the claims.

If any additional fees are due in connection with the filing of this paper, please charge the fees to our Deposit Account No. 16-2312. If a fee is required for an extension of time under 37 C.F.R. § 1.136 not accounted for above, such an extension is requested and the fee should also be charged to our deposit account.

Respectfully submitted,

Date: November 15, 2005

By Patrick J. O'Connell
Customer No. 009561
Patrick J. O'Connell (33,984)
POPOVICH, WILES & O'CONNELL, P.A.
650 Third Avenue South, Suite 600
Minneapolis, MN 55402
Telephone: (612) 334-8989
Attorney for Applicants